Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up to one of the world’s leading biotech companies. Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases, such as Pompe disease, for over 30 years.

 

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, such as GNE myopathy.

 

The mission of the LGMD2i Fund is to expedite the development of a treatment or cure for LGMD2I, by supporting the most promising research projects, and coordinating and managing the scientific process.

 

The Samantha J Brazzo Foundation  was founded when, at the age of two, Samantha was diagnosed LGMD2I . It supports facilities that aim to establish a treatment or cure for LGMD2I.

 

In addition to educating patients and physicians, the LGMD2D Foundation maintains a patient registry, funds and monitors research and progress, provides financial support to accelerate clinical trials, and encourages scientific collaboration.

 

The Kurt+Peter Foundation was formed by the family and friends of two young boys, Kurt and Peter, who were diagnosed with LGMD2C. The Kurt+Peter Foundation aims to take affirmative action to apply promising research to LGMD2C, raising funds to apply current science to potential therapies for the disease.